Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 20.
doi: 10.1111/jdv.20876. Online ahead of print.

Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema (TREAT) registry taskforce

A H Musters  1 , L A A Gerbens  1 , L van der Gang  1   2 , M A Middelkamp-Hup  1 , W Ouwerkerk  1   3 , D J Hijnen  4 , E Haufe  5 , L Heinrich  5 , T Werfel  6 , S Weidinger  7 , J Schmitt  5 , A Svedbom  8   9 , E K Johansson  8   9 , M Bradley  8   9 , L B von Kobyletzki  10   11 , I Vittrup  12 , I F Ruge  12   13 , J P Thyssen  14 , C Vestergaard  15 , J M Carrascosa  16 , M de Vega  17 , I García-Doval  17 , A Chiricozzi  18   19 , L Stingeni  20 , P Calzavara-Pinton  21 , M R Ardern-Jones  22   23 , N J Reynolds  24   25 , C Flohr  26 , P I Spuls  1 ; A‐STAR, AtopyReg, BIOBADATOP, SCRATCH, SwedAD, TREATgermany and TREAT NL/BE registry teams
Collaborators, Affiliations

Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema (TREAT) registry taskforce

A H Musters et al. J Eur Acad Dermatol Venereol. .

Abstract

Background: The TREAT Registry Taskforce is a collaborative effort of international registries aiming to provide real-world data on the long-term efficacy, cost-effectiveness and safety of systemic treatments and phototherapy for atopic eczema (AE).

Objectives: This study seeks to present a comprehensive overview of the demographics, prior systemic treatments, clinical characteristics and disease severity and burden at baseline among patients enrolled in seven TREAT registries. Moreover, the aim is to gain insight into the differences between the registries and to explore the current prescribing practices of various therapies for patients with AE across Europe.

Methods: Data from June 2016 to 31 October 2022, were collected from seven observational cohorts: A-STAR (UK/Ireland), AtopyReg (Italy), Biobadatop (Spain), SCRATCH (Denmark), SwedAD (Sweden), TREATgermany (Germany) and TREAT NL/BE (Netherlands/Belgium).

Results: The analysis included 5337 patients, with a mean age of 39.1 years (6.3% paediatric, 54.4% male). Of these, 84.1% had previously received systemic treatments, primarily systemic corticosteroids (58.8%) and ciclosporin (39.0%), while 30.1% had undergone phototherapy. At enrolment, dupilumab was the most prescribed treatment (75.0%), followed by ciclosporin (7.8%) and Janus Kinase inhibitors (5.9%); only 1.7% started phototherapy. Baseline assessments showed that most patients had moderate (41.9%) to severe (30.1%) AE, with an average Eczema Area and Severity Index (EASI) score of 17.6. The Patient-Oriented Eczema Measure (POEM) score averaged 17.2, indicating severe disease impact. The Dermatology Life Quality Index (DLQI) score averaged 13.4, and the Numerical Rating Scale (NRS) for itch was 6.4.

Conclusions: This pooled analysis from the TREAT Registry Taskforce highlights the variability and similarities in data collection across national registries, providing significant insights into the baseline characteristics of the patient population. It establishes a robust foundation for future analyses of key effectiveness and safety outcomes.

Keywords: atopic dermatitis; atopic eczema; baseline; demographics; disease burden; disease severity; patient‐reported outcomes; phototherapy; real‐world data; registry; systemic immunomodulating treatment.

PubMed Disclaimer

References

REFERENCES

    1. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: report of the nomenclature review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832–836.
    1. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI. Global variations in prevalence of eczema symptoms in children from ISAAC phase three. J Allergy Clin Immunol. 2009;124(6):1251–1258.e23.
    1. Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB, Manuel JC. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005;22(3):192–199. https://doi.org/10.1111/j.1525‐1470.2005.22303.x
    1. Langan SM, Alan ID, Weidinger S. Atopic dermatitis. Lancet. 2020;369:345–360.
    1. Taylor K, Swan DJ, Affleck A, Flohr C, Reynolds NJ. Treatment of moderate‐to‐severe atopic eczema in adults within the U.K.: results of a national survey of dermatologists. Br J Dermatol. 2017;176(6):1617–1623. https://doi.org/10.1111/bjd.15235

LinkOut - more resources